Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:EW
- CUSIP: 28176E10
- Web: www.edwards.com
Capitalization:- Market Cap: $23.3 billion
- Outstanding Shares: 211,158,000
Average Prices:- 50 Day Moving Avg: $113.80
- 200 Day Moving Avg: $109.37
- 52 Week Range: $81.12 - $121.75
P/E:- Trailing P/E Ratio: 33.89
- Foreward P/E Ratio: 26.39
- P/E Growth: 1.80
Sales & Book Value:- Annual Revenue: $3.23 billion
- Price / Sales: 7.21
- Book Value: $13.93 per share
- Price / Book: 7.92
Profitability:- EBIDTA: $1.05 billion
- Net Margins: 22.16%
- Return on Equity: 27.17%
- Return on Assets: 15.91%
Debt:- Debt-to-Equity Ratio: 0.35%
- Current Ratio: 4.06%
- Quick Ratio: 3.19%
Misc:- Average Volume: 1.23 million shs.
- Beta: 0.64
- Short Ratio: 1.54
Frequently Asked Questions for Edwards Lifesciences Corporation (NYSE:EW)
What is Edwards Lifesciences Corporation's stock symbol?
Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences Corporation's stock split? How did Edwards Lifesciences Corporation's stock split work?
Shares of Edwards Lifesciences Corporation split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.
How were Edwards Lifesciences Corporation's earnings last quarter?
Edwards Lifesciences Corporation (NYSE:EW) released its quarterly earnings data on Wednesday, July, 26th. The company reported $1.08 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.20. The company earned $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation's revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $0.76 EPS. View Edwards Lifesciences Corporation's Earnings History.
When will Edwards Lifesciences Corporation make its next earnings announcement?
What guidance has Edwards Lifesciences Corporation issued on next quarter's earnings?
Edwards Lifesciences Corporation updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $3.65-3.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.54. The company issued revenue guidance of $, compared to the consensus revenue estimate of $3.35 billion.Edwards Lifesciences Corporation also updated its Q3 guidance to $0.80-0.90 EPS.
Where is Edwards Lifesciences Corporation's stock going? Where will Edwards Lifesciences Corporation's stock price be in 2017?
20 equities research analysts have issued 1 year price targets for Edwards Lifesciences Corporation's stock. Their predictions range from $14.00 to $155.00. On average, they anticipate Edwards Lifesciences Corporation's stock price to reach $120.05 in the next twelve months. View Analyst Ratings for Edwards Lifesciences Corporation.
What are analysts saying about Edwards Lifesciences Corporation stock?
Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:
- 1. According to Zacks Investment Research, "Over the last three months, Edwards Lifesciences has outperformed the Zacks categorized Medical - Instruments industry. We believe several recent FDA approvals received by the company including its SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting the investors’ confidence over the stock. Also, Edwards Lifesciences’ long-term growth strategy buoys optimism. The company’s focus on bulding its pipeline to strengthen its foothold across all its operating businesses is also encouraging. However, higher operating expenses continue to be a woe. The stock’s valuation also remains stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (7/18/2017)
- 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
Who are some of Edwards Lifesciences Corporation's key competitors?
Some companies that are related to Edwards Lifesciences Corporation include Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR) and Natus Medical Incorporated (BABY).
Who are Edwards Lifesciences Corporation's key executives?
Edwards Lifesciences Corporation's management team includes the folowing people:
- Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
- Scott B. Ullem, Chief Financial Officer, Corporate Vice President
- Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
- Catherine M. Szyman, Corporate Vice President- Critical Care
- Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
- Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
- Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
- Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
- Kieran T. Gallahue, Independent Director
- Leslie Stone Heisz, Independent Director
Who owns Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.83%), BlackRock Inc. (6.68%), State Street Corp (4.31%), Alliancebernstein L.P. (2.82%), Bank of New York Mellon Corp (2.52%) and Ameriprise Financial Inc. (2.06%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences Corporation.
Who sold Edwards Lifesciences Corporation stock? Who is selling Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., FMR LLC, Fred Alger Management Inc., Voya Investment Management LLC, Marshall Wace North America L.P., Winslow Capital Management LLC, Alliancebernstein L.P. and State Street Corp. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Huimin Wang, Larry L Wood, Michael A Mussallem and Patrick B Verguet. View Insider Buying and Selling for Edwards Lifesciences Corporation.
Who bought Edwards Lifesciences Corporation stock? Who is buying Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Egerton Capital UK LLP, Koch Industries Inc., Artisan Partners Limited Partnership, Harbour Capital Advisors LLC, Vanguard Group Inc., Wells Fargo & Company MN and Delta Lloyd Asset Management N.V.. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences Corporation.
How do I buy Edwards Lifesciences Corporation stock?
Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edwards Lifesciences Corporation's stock price today?
One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $110.33.
MarketBeat Community Rating for Edwards Lifesciences Corporation (NYSE EW)MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Edwards Lifesciences Corporation (NYSE:EW) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 14 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $120.05 (8.81% upside) |
Analysts' Ratings History for Edwards Lifesciences Corporation (NYSE:EW)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/1/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $130.00 | N/A |  |
| 9/1/2017 | BMO Capital Markets | Reiterated Rating | Buy | $132.00 | N/A | |
| 8/28/2017 | William Blair | Reiterated Rating | Outperform -> Outperform | | Low | |
| 7/30/2017 | Canaccord Genuity | Reiterated Rating | Buy | $150.00 -> $155.00 | Low | |
| 7/27/2017 | Cowen and Company | Reiterated Rating | Outperform | $130.00 -> $135.00 | Low | |
| 7/27/2017 | Barclays PLC | Boost Price Target | Equal Weight | $108.00 -> $120.00 | Low | |
| 7/27/2017 | Stifel Nicolaus | Reiterated Rating | Buy -> Buy | $118.00 -> $130.00 | High | |
| 7/27/2017 | Bank of America Corporation | Boost Price Target | Positive -> Buy | $140.00 -> $150.00 | High | |
| 7/27/2017 | Jefferies Group LLC | Boost Price Target | Buy | $115.00 -> $132.00 | High | |
| 7/17/2017 | SunTrust Banks, Inc. | Boost Price Target | Buy | $14.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Conviction-Buy | $138.00 | Low | |
| 3/27/2017 | Evercore ISI | Upgrade | In-Line -> Outperform | $98.50 -> $110.00 | Low | |
| 3/20/2017 | Northland Securities | Set Price Target | Buy | $105.00 | Low | |
| 2/8/2017 | Credit Suisse Group | Set Price Target | Buy | $120.00 | N/A | |
| 2/5/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $100.00 | N/A | |
| 2/2/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | | N/A | |
| 2/2/2017 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 1/3/2017 | Guggenheim | Upgrade | Neutral -> Buy | $120.00 | N/A | |
| 12/10/2016 | JMP Securities | Reiterated Rating | Equal Weight | $130.00 | N/A | |
| 12/1/2016 | J P Morgan Chase & Co | Set Price Target | Buy | $120.00 | N/A | |
| 9/11/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 8/19/2016 | Morgan Stanley | Reiterated Rating | Buy | $140.00 | N/A | |
| 7/27/2016 | Citigroup Inc. | Boost Price Target | Sell | $86.00 -> $94.00 | N/A | |
| 6/21/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $123.00 | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $101.00 | N/A | |
| 1/4/2016 | Sterne Agee CRT | Boost Price Target | Buy | $90.00 -> $92.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Edwards Lifesciences Corporation (NYSE:EW)Earnings History by Quarter for Edwards Lifesciences Corporation (NYSE EW)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/23/2017 | | $0.83 | | | | | N/A | |
| 7/26/2017 | Q2 2017 | $0.88 | $1.08 | $839.16 million | $842.00 million | View | N/A | |
| 4/25/2017 | Q1 2017 | $0.82 | $0.94 | $776.51 million | $883.50 million | View | N/A | |
| 2/1/2017 | Q416 | $0.72 | $0.75 | $760.85 million | $767.70 million | View | N/A | |
| 10/25/2016 | Q316 | $0.68 | $0.68 | $749.14 million | $739.40 million | View | N/A | |
| 7/26/2016 | Q216 | $0.70 | $0.76 | $724.26 million | $759.30 million | View | N/A | |
| 4/26/2016 | Q116 | $0.66 | $0.71 | $664.53 million | $697.30 million | View | N/A | |
| 2/2/2016 | Q415 | $0.62 | $0.63 | $647.44 million | $671.10 million | View | N/A | |
| 10/26/2015 | Q315 | $0.98 | $1.07 | $598.29 million | $615.00 million | View | N/A | |
| 7/28/2015 | Q215 | $1.05 | $1.13 | $604.97 million | $616.80 million | View | N/A | |
| 4/23/2015 | Q115 | $1.04 | $1.12 | $585.16 million | $590.30 million | View | N/A | |
| 2/3/2015 | Q414 | $0.95 | $1.06 | $610.50 million | $618.00 million | View | Listen | |
| 10/23/2014 | Q314 | $0.72 | $0.80 | $546.10 million | $607.40 million | View | Listen | |
| 7/29/2014 | Q214 | $0.77 | $0.88 | $545.10 million | $547.00 million | View | Listen | |
| 4/24/2014 | Q114 | $0.69 | $0.76 | $523.10 million | $522.40 million | View | Listen | |
| 2/3/2014 | Q413 | $0.82 | $0.91 | $533.82 million | $536.00 million | View | N/A | |
| 10/28/2013 | Q313 | $0.66 | $0.68 | $490.96 million | $496.00 million | View | N/A | |
| 7/25/2013 | Q2 2013 | $0.76 | $0.82 | $514.59 million | $517.20 million | View | N/A | |
| 4/23/2013 | Q1 2013 | $0.76 | $0.72 | $518.69 million | $496.70 million | View | N/A | |
| 2/4/2013 | Q4 2012 | $0.77 | $0.77 | $499.46 million | $510.50 million | View | N/A | |
| 10/19/2012 | | $0.56 | $0.58 | | | View | N/A | |
| 7/24/2012 | | $0.66 | $0.67 | | | View | N/A | |
| 2/2/2012 | | $0.59 | $0.62 | | | View | N/A | |
| 10/19/2011 | | $0.39 | $0.38 | | | View | N/A | |
| 7/21/2011 | | $0.50 | $0.49 | | | View | N/A | |
| 4/20/2011 | | $0.42 | $0.51 | | | View | N/A | |
| 2/2/2011 | | $0.53 | $0.55 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Edwards Lifesciences Corporation (NYSE:EW)2017 EPS Consensus Estimate: $3.44
2018 EPS Consensus Estimate: $4.05
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $0.82 | $0.85 | $0.84 |
| Q2 2017 | 4 | $0.87 | $0.89 | $0.88 |
| Q3 2017 | 4 | $0.79 | $0.86 | $0.84 |
| Q4 2017 | 4 | $0.88 | $0.92 | $0.89 |
| Q1 2018 | 3 | $0.95 | $1.10 | $1.03 |
| Q2 2018 | 3 | $1.04 | $1.09 | $1.06 |
| Q3 2018 | 3 | $0.92 | $0.98 | $0.95 |
| Q4 2018 | 3 | $0.96 | $1.05 | $1.02 |
(Data provided by Zacks Investment Research)
Dividend History for Edwards Lifesciences Corporation (NYSE:EW)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Edwards Lifesciences Corporation (NYSE:EW)Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 82.08%
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | Larry L. Wood | VP | Sell | 18,960 | $112.58 | $2,134,516.80 | |
| 9/7/2017 | Michael A. Mussallem | CEO | Sell | 32,900 | $112.45 | $3,699,605.00 | |
| 8/30/2017 | Larry L. Wood | VP | Sell | 18,960 | $111.81 | $2,119,917.60 | |
| 8/29/2017 | Donald E. Bobo, Jr. | VP | Sell | 5,300 | $112.15 | $594,395.00 | |
| 8/9/2017 | Michael A. Mussallem | CEO | Sell | 32,900 | $115.99 | $3,816,071.00 | |
| 8/4/2017 | Donald E. Bobo, Jr. | VP | Sell | 25,000 | $116.00 | $2,900,000.00 | |
| 7/31/2017 | Catherine M. Szyman | VP | Sell | 4,681 | $115.78 | $541,966.18 | |
| 7/31/2017 | Michael A. Mussallem | CEO | Sell | 32,900 | $114.80 | $3,776,920.00 | |
| 7/28/2017 | Donald E. Bobo, Jr. | VP | Sell | 5,300 | $114.68 | $607,804.00 | |
| 6/29/2017 | Donald E. Bobo, Jr. | VP | Sell | 5,600 | $117.15 | $656,040.00 | |
| 6/7/2017 | Michael A. Mussallem | CEO | Sell | 32,900 | $118.05 | $3,883,845.00 | |
| 5/31/2017 | Patrick B. Verguet | VP | Sell | 10,000 | $114.88 | $1,148,800.00 | |
| 5/19/2017 | Dylan Sidoo | Director | Buy | 25,000 | $0.11 | $2,750.00 | |
| 5/19/2017 | Patrick B. Verguet | VP | Sell | 22,631 | $113.16 | $2,560,923.96 | |
| 5/15/2017 | Patrick B. Verguet | VP | Sell | 11,500 | $111.64 | $1,283,860.00 | |
| 5/8/2017 | Donald E. Bobo, Jr. | VP | Sell | 19,100 | $110.34 | $2,107,494.00 | |
| 5/4/2017 | Donald E. Bobo, Jr. | VP | Sell | 34,120 | $109.98 | $3,752,517.60 | |
| 5/3/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $109.71 | $5,386,761.00 | |
| 4/28/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $109.78 | $5,390,198.00 | |
| 4/27/2017 | Bernard J. Zovighian | VP | Sell | 18,050 | $109.21 | $1,971,240.50 | |
| 4/5/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $93.58 | $1,283,917.60 | |
| 3/30/2017 | Patrick B. Verguet | VP | Sell | 24,000 | $93.90 | $2,253,600.00 | |
| 3/6/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $90.01 | $1,234,937.20 | |
| 2/16/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $89.63 | $4,400,833.00 | |
| 2/3/2017 | Kieran Gallahue | Director | Buy | 3,000 | $90.10 | $270,300.00 | |
| 1/13/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $97.08 | $4,766,628.00 | |
| 1/12/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $97.47 | $1,337,288.40 | |
| 1/12/2017 | Dylan Sidoo | Director | Buy | 30,000 | $0.13 | $3,900.00 | |
| 1/11/2017 | Dylan Sidoo | Director | Buy | 20,000 | $0.13 | $2,600.00 | |
| 12/19/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $91.96 | $4,515,236.00 | |
| 12/5/2016 | Huimin Wang | VP | Sell | 13,650 | $83.53 | $1,140,184.50 | |
| 12/1/2016 | Larry L. Wood | VP | Sell | 13,258 | $81.85 | $1,085,167.30 | |
| 11/30/2016 | Catherine M. Szyman | VP | Buy | 12,870 | $83.43 | $1,073,744.10 | |
| 11/29/2016 | Kieran Gallahue | Director | Buy | 3,000 | $84.63 | $253,890.00 | |
| 11/22/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $84.67 | $4,157,297.00 | |
| 11/7/2016 | Huimin Wang | VP | Sell | 13,650 | $91.29 | $1,246,108.50 | |
| 11/2/2016 | Donald E. Bobo, Jr. | VP | Sell | 15,000 | $90.13 | $1,351,950.00 | |
| 11/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $93.27 | $1,236,480.39 | |
| 10/27/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $92.77 | $4,555,007.00 | |
| 10/5/2016 | Huimin Wang | VP | Sell | 13,650 | $120.04 | $1,638,546.00 | |
| 10/3/2016 | Larry L. Wood | VP | Sell | 13,257 | $119.27 | $1,581,162.39 | |
| 9/6/2016 | Huimin Wang | VP | Sell | 13,650 | $115.72 | $1,579,578.00 | |
| 9/2/2016 | Donald E. Bobo, Jr. | VP | Sell | 18,000 | $115.78 | $2,084,040.00 | |
| 8/26/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $114.88 | $574,400.00 | |
| 8/24/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $116.81 | $584,050.00 | |
| 8/23/2016 | Patrick B. Verguet | VP | Sell | 10,092 | $117.53 | $1,186,112.76 | |
| 8/11/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $114.01 | $5,597,891.00 | |
| 8/10/2016 | John T. Cardis | Director | Sell | 5,000 | $113.21 | $566,050.00 | |
| 8/9/2016 | Patrick B. Verguet | VP | Sell | 10,000 | $113.48 | $1,134,800.00 | |
| 8/5/2016 | Huimin Wang | VP | Sell | 13,650 | $113.03 | $1,542,859.50 | |
| 8/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $114.24 | $1,514,479.68 | |
| 8/1/2016 | Schack Wesley W. Von | Director | Sell | 6,000 | $113.98 | $683,880.00 | |
| 7/29/2016 | Robert W.A. Sellers | VP | Sell | 10,000 | $114.33 | $1,143,300.00 | |
| 7/28/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $113.31 | $5,563,521.00 | |
| 7/5/2016 | Huimin Wang | VP | Sell | 13,650 | $98.44 | $1,343,706.00 | |
| 7/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $98.79 | $1,309,659.03 | |
| 6/8/2016 | Michael A Mussallem | CEO | Sell | 49,100 | $102.75 | $5,045,025.00 | |
| 6/6/2016 | Huimin Wang | VP | Sell | 13,650 | $101.34 | $1,383,291.00 | |
| 6/3/2016 | Larry L Wood | VP | Sell | 13,257 | $101.38 | $1,343,994.66 | |
| 5/31/2016 | Donald E Bobo Jr | VP | Sell | 18,000 | $99.04 | $1,782,720.00 | |
| 5/24/2016 | Steven R Loranger | Director | Buy | 5,000 | $101.07 | $505,350.00 | |
| 5/18/2016 | Patrick B Verguet | VP | Sell | 13,000 | $102.75 | $1,335,750.00 | |
| 5/17/2016 | Patrick B Verguet | VP | Sell | 5,000 | $105.00 | $525,000.00 | |
| 5/16/2016 | Patrick B Verguet | VP | Sell | 3,000 | $104.62 | $313,860.00 | |
| 5/5/2016 | Huimin Wang | VP | Sell | 13,650 | $103.36 | $1,410,864.00 | |
| 5/5/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $104.12 | $6,143,080.00 | |
| 5/2/2016 | Patrick B Verguet | VP | Sell | 7,000 | $106.86 | $748,020.00 | |
| 4/29/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $106.13 | $6,261,670.00 | |
| 4/5/2016 | Huimin Wang | VP | Sell | 13,650 | $103.97 | $1,419,190.50 | |
| 3/17/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $84.39 | $4,979,010.00 | |
| 3/7/2016 | Huimin Wang | VP | Sell | 13,650 | $87.17 | $1,189,870.50 | |
| 2/18/2016 | Michael A. Mussallem | CEO | Sell | 59,000 | $86.94 | $5,129,460.00 | |
| 2/18/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $87.00 | $435,000.00 | |
| 2/16/2016 | Patrick B. Verguet | VP | Sell | 8,000 | $81.58 | $652,640.00 | |
| 2/5/2016 | Huimin Wang | VP | Sell | 13,650 | $83.46 | $1,139,229.00 | |
| 2/4/2016 | Barbara J. Mcneil | Director | Sell | 4,000 | $83.29 | $333,160.00 | |
| 1/21/2016 | Patrick B. Verguet | VP | Sell | 8,000 | $77.00 | $616,000.00 | |
| 1/6/2016 | Nick Demare | Director | Buy | 15,000 | $0.08 | $1,200.00 | |
| 1/5/2016 | Huimin Wang | VP | Sell | 13,650 | $78.50 | $1,071,525.00 | |
| 1/5/2016 | Michael A. Mussallem | CEO | Sell | 59,000 | $79.82 | $4,709,380.00 | |
| 12/17/2015 | Michael A. Mussallem | CEO | Sell | 59,000 | $81.85 | $4,829,150.00 | |
| 12/15/2015 | Patrick B. Verguet | VP | Sell | 8,000 | $80.87 | $646,960.00 | |
| 12/4/2015 | Huimin Wang | VP | Sell | 6,880 | $157.96 | $1,086,764.80 | |
| 11/27/2015 | Patrick B. Verguet | VP | Sell | 7,500 | $164.50 | $1,233,750.00 | |
| 11/23/2015 | Robert W.A. Sellers | VP | Sell | 19,200 | $157.13 | $3,016,896.00 | |
| 11/17/2015 | Patrick B. Verguet | VP | Sell | 4,000 | $154.50 | $618,000.00 | |
| 11/5/2015 | Huimin Wang | VP | Sell | 6,920 | $156.01 | $1,079,589.20 | |
| 11/3/2015 | Patrick B. Verguet | VP | Sell | 4,338 | $158.48 | $687,486.24 | |
| 10/30/2015 | Patrick B. Verguet | VP | Sell | 22,000 | $155.09 | $3,411,980.00 | |
| 10/29/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $154.59 | $4,560,405.00 | |
| 10/5/2015 | Huimin Wang | VP | Sell | 6,920 | $154.30 | $1,067,756.00 | |
| 10/2/2015 | Patrick B. Verguet | VP | Sell | 4,000 | $154.00 | $616,000.00 | |
| 10/1/2015 | Larry L. Wood | VP | Sell | 7,680 | $141.52 | $1,086,873.60 | |
| 9/21/2015 | Michael A. Mussallem | CEO | Sell | 29,500 | $142.49 | $4,203,455.00 | |
| 9/4/2015 | Huimin Wang | VP | Sell | 6,920 | $135.19 | $935,514.80 | |
| 9/1/2015 | Larry L. Wood | VP | Sell | 7,680 | $137.50 | $1,056,000.00 | |
| 8/24/2015 | Michael A. Mussallem | CEO | Sell | 29,500 | $135.25 | $3,989,875.00 | |
| 8/13/2015 | West Petroleum Corp. East | Insider | Buy | 25,000 | $0.12 | $2,875.00 | |
| 7/6/2015 | Huimin Wang | VP | Sell | 6,920 | $143.95 | $996,134.00 | |
| 7/1/2015 | Larry L Wood | VP | Sell | 7,680 | $143.51 | $1,102,156.80 | |
| 6/24/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $143.71 | $4,239,445.00 | |
| 6/5/2015 | Huimin Wang | VP | Sell | 6,920 | $131.39 | $909,218.80 | |
| 6/1/2015 | Larry L Wood | VP | Sell | 7,680 | $130.47 | $1,002,009.60 | |
| 5/29/2015 | Patrick B Verguet | VP | Sell | 9,662 | $131.18 | $1,267,461.16 | |
| 5/21/2015 | Barbara J Mcneil | Director | Sell | 2,000 | $132.59 | $265,180.00 | |
| 5/19/2015 | Robert Marc Bustin | Director | Sell | 10,000 | $0.18 | $1,750.00 | |
| 5/1/2015 | Larry L Wood | VP | Sell | 7,680 | $127.12 | $976,281.60 | |
| 4/30/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $128.99 | $3,805,205.00 | |
| 4/6/2015 | Huimin Wang | VP | Sell | 6,920 | $140.24 | $970,460.80 | |
| 4/1/2015 | Larry L Wood | VP | Sell | 7,680 | $142.06 | $1,091,020.80 | |
| 3/31/2015 | Robert Marc Bustin | Director | Buy | 15,000 | $0.15 | $2,250.00 | |
| 3/26/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $140.10 | $4,132,950.00 | |
| 3/2/2015 | Larry L Wood | VP | Sell | 7,680 | $132.62 | $1,018,521.60 | |
| 2/6/2015 | Huimin Wang | VP | Sell | 6,920 | $134.79 | $932,746.80 | |
| 1/5/2015 | Huimin Wang | VP | Sell | 6,920 | $126.60 | $876,072.00 | |
| 1/5/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $128.20 | $3,781,900.00 | |
| 12/22/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $133.01 | $3,923,795.00 | |
| 11/24/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $124.25 | $3,665,375.00 | |
| 11/13/2014 | Robert W.A. Sellers | VP | Sell | 3,400 | $124.27 | $422,518.00 | |
| 11/10/2014 | Patrick B Verguet | VP | Sell | 5,000 | $123.70 | $618,500.00 | |
| 11/7/2014 | Schack Wesley W Von | Director | Sell | 3,655 | $123.00 | $449,565.00 | |
| 11/5/2014 | Huimin Wang | VP | Sell | 5,600 | $120.26 | $673,456.00 | |
| 10/28/2014 | Barbara J Mcneil | Director | Sell | 1,000 | $117.94 | $117,940.00 | |
| 10/28/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $117.06 | $3,453,270.00 | |
| 10/28/2014 | Patrick B Verguet | VP | Sell | 15,000 | $117.33 | $1,759,950.00 | |
| 10/28/2014 | West Petroleum Corp. East | Insider | Buy | 15,000 | $0.12 | $1,800.00 | |
| 10/27/2014 | Patrick B Verguet | VP | Sell | 10,000 | $117.00 | $1,170,000.00 | |
| 10/27/2014 | West Petroleum Corp. East | Insider | Buy | 20,000 | $0.13 | $2,600.00 | |
| 10/24/2014 | Donald E Bobo Jr | VP | Sell | 30,000 | $114.25 | $3,427,500.00 | |
| 10/24/2014 | West Petroleum Corp. East | Insider | Buy | 35,000 | $0.14 | $4,725.00 | |
| 10/23/2014 | West Petroleum Corp. East | Insider | Buy | 40,000 | $0.15 | $5,800.00 | |
| 10/6/2014 | Huimin Wang | VP | Sell | 5,600 | $107.00 | $599,200.00 | |
| 10/3/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $105.00 | $2,625,000.00 | |
| 9/29/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $102.71 | $3,029,945.00 | |
| 9/10/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $100.00 | $2,500,000.00 | |
| 9/5/2014 | Huimin Wang | VP | Sell | 5,600 | $98.29 | $550,424.00 | |
| 8/27/2014 | Carlyn D Solomon | VP | Sell | 85,200 | $97.85 | $8,336,820.00 | |
| 8/27/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $98.14 | $2,895,130.00 | |
| 8/18/2014 | John T Cardis | Director | Sell | 6,000 | $97.92 | $587,520.00 | |
| 8/18/2014 | Larry L Wood | VP | Sell | 63,752 | $97.85 | $6,238,133.20 | |
| 8/13/2014 | Patrick B Verguet | VP | Sell | 7,800 | $95.50 | $744,900.00 | |
| 8/5/2014 | Patrick B Verguet | VP | Sell | 15,000 | $94.05 | $1,410,750.00 | |
| 8/4/2014 | Patrick B Verguet | VP | Sell | 5,000 | $93.00 | $465,000.00 | |
| 8/1/2014 | Patrick B Verguet | VP | Sell | 5,000 | $92.00 | $460,000.00 | |
| 7/31/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $91.98 | $2,713,410.00 | |
| 7/31/2014 | Robert Alexander Ingram | Director | Sell | 12,500 | $90.26 | $1,128,250.00 | |
| 7/31/2014 | Robert W.A. Sellers | VP | Sell | 8,850 | $91.47 | $809,509.50 | |
| 7/30/2014 | Donald E Bobo Jr | VP | Sell | 23,270 | $92.00 | $2,140,840.00 | |
| 7/7/2014 | Huimin Wang | VP | Sell | 5,600 | $87.79 | $491,624.00 | |
| 6/27/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $87.00 | $2,175,000.00 | |
| 6/24/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $85.38 | $2,518,710.00 | |
| 6/5/2014 | Huimin Wang | VP | Sell | 5,600 | $80.73 | $452,088.00 | |
| 5/30/2014 | Barbara J Mcneil | Director | Sell | 1,200 | $81.20 | $97,440.00 | |
| 5/28/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $79.33 | $2,340,235.00 | |
| 4/14/2014 | Donald Bobo, Jr. | VP | Sell | 25,000 | $82.00 | $2,050,000.00 | |
| 4/10/2014 | Michael Mussallem | CEO | Sell | 29,500 | $74.71 | $2,203,945.00 | |
| 4/7/2014 | Huimin Wang | VP | Sell | 5,600 | $74.03 | $414,568.00 | |
| 3/24/2014 | Michael Bowlin | Director | Sell | 1,093 | $72.33 | $79,056.69 | |
| 3/6/2014 | Robert W.A. Sellers | VP | Sell | 1,650 | $72.88 | $120,252.00 | |
| 2/6/2014 | Michael Mussallem | CEO | Sell | 29,500 | $66.92 | $1,974,140.00 | |
| 1/27/2014 | Michael Bowlin | Director | Sell | 1,092 | $68.65 | $74,965.80 | |
| 1/9/2014 | Michael Mussallem | CEO | Sell | 29,500 | $67.04 | $1,977,680.00 | |
| 1/6/2014 | Huimin Wang | VP | Sell | 5,600 | $67.14 | $375,984.00 | |
| 12/11/2013 | Patrick Verguet | VP | Sell | 10,000 | $62.34 | $623,400.00 | |
| 12/5/2013 | Huimin Wang | VP | Sell | 4,650 | $64.65 | $300,622.50 | |
| 12/4/2013 | Michael Mussallem | CEO | Sell | 29,500 | $64.90 | $1,914,550.00 | |
| 10/9/2013 | Michael Mussallem | CEO | Sell | 29,500 | $72.63 | $2,142,585.00 | |
| 10/4/2013 | Huimin Wang | VP | Sell | 4,850 | $72.19 | $350,121.50 | |
| 9/12/2013 | Michael Mussallem | CEO | Sell | 29,500 | $71.82 | $2,118,690.00 | |
| 9/5/2013 | Huimin Wang | VP | Sell | 4,850 | $71.24 | $345,514.00 | |
| 8/8/2013 | Michael Mussallem | CEO | Sell | 29,500 | $72.28 | $2,132,260.00 | |
| 8/5/2013 | Huimin Wang | VP | Sell | 4,850 | $72.30 | $350,655.00 | |
| 8/1/2013 | Patrick Verguet | VP | Sell | 20,000 | $73.15 | $1,463,000.00 | |
| 7/10/2013 | Michael A Mussallem | CEO | Sell | 29,500 | $65.60 | $1,935,200.00 | |
| 7/5/2013 | Huimin Wang | VP | Sell | 4,850 | $65.69 | $318,596.50 | |
| 6/6/2013 | Michael A Mussallem | CEO | Sell | 29,500 | $66.25 | $1,954,375.00 | |
| 6/5/2013 | Huimin Wang | VP | Sell | 4,850 | $65.11 | $315,783.50 | |
| 5/13/2013 | Paul C Redmond | VP | Sell | 5,000 | $67.35 | $336,750.00 | |
| 5/8/2013 | Michael A Mussallem | CEO | Sell | 29,200 | $64.24 | $1,875,808.00 | |
| 5/7/2013 | Thomas M Abate | CFO | Sell | 15,000 | $63.75 | $956,250.00 | |
| 5/3/2013 | Schack Wesley W Von | Director | Buy | 1,000 | $64.00 | $64,000.00 | |
| 5/1/2013 | David E I Pyott | Director | Buy | 3,000 | $62.95 | $188,850.00 | |
| 5/1/2013 | John H Kehl Jr | VP | Sell | 12,500 | $62.72 | $784,000.00 | |
| 4/26/2013 | Schack Wesley W Von | Director | Buy | 2,000 | $64.95 | $129,900.00 | |
| 4/10/2013 | Michael A Mussallem | CEO | Sell | 35,000 | $83.37 | $2,917,950.00 | |
| 3/13/2013 | John H Kehl Jr | VP | Sell | 12,500 | $87.75 | $1,096,875.00 | |
| 10/5/2012 | Huimin Wang | VP | Sell | 6,250 | $109.88 | $686,750.00 | |
| 10/4/2012 | Donald E Bobo Jr | VP | Sell | 11,530 | $110.14 | $1,269,914.20 | |
| 8/9/2012 | Michael A Mussallem | CEO | Sell | 35,000 | $98.69 | $3,454,150.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Edwards Lifesciences Corporation (NYSE:EW)
Latest Headlines for Edwards Lifesciences Corporation (NYSE:EW)
| Source: |
|
| Date | Headline |
|---|
 | Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?
finance.yahoo.com - September 21 at 6:38 PM |
 | Halyard Health (HYH) Announces Positive Data on COOLIEF - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM |
| Boston Scientific MultiSENSE Study on HeartLogic Positive - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM |
| Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM |
| Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1 - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM |
| Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
finance.yahoo.com - September 19 at 6:28 PM |
| Surmodics Receives FDA's Approval for PTA Balloon Catheter
finance.yahoo.com - September 19 at 6:28 PM |
 | Edwards Lifesciences Corporation (EW) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - September 19 at 10:51 AM |
| Insider Selling: Edwards Lifesciences Corporation (EW) VP Sells 18,960 Shares of Stock
www.americanbankingnews.com - September 18 at 7:22 PM |
| McKesson to Gain From Distribution Business Amid Pricing Woes
finance.yahoo.com - September 18 at 6:17 PM |
| Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet ... - Nasdaq
www.nasdaq.com - September 15 at 7:03 PM |
| Thermo Fisher Fundamentals Impressive Amid Tough Competition - Nasdaq
www.nasdaq.com - September 15 at 7:03 PM |
| Allscripts' Latest Initiative Eradicates Price Ambiguity
finance.yahoo.com - September 15 at 7:03 PM |
| Phibro Animal Health Expands Globally Amid Tough Competition
finance.yahoo.com - September 15 at 7:03 PM |
| Edwards Lifesciences Corporation (EW) versus Illumina (ILMN) Head to Head Survey
www.americanbankingnews.com - September 15 at 6:29 PM |
 | Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod
www.msn.com - September 14 at 7:08 PM |
 | Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare
www.zacks.com - September 14 at 7:08 PM |
| Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod
finance.yahoo.com - September 14 at 7:08 PM |
| Here's Why Investors Should Buy Luminex (LMNX) Right Now
finance.yahoo.com - September 14 at 7:08 PM |
| Genomic Health Ties up With Biocartis, Boosts Oncotype DX
finance.yahoo.com - September 14 at 7:08 PM |
| NuVasive Launches Breakthrough in MIS Surgery -- LessRay
finance.yahoo.com - September 14 at 7:08 PM |
| Medtronic Launches StealthStation Technology, Expands in ENT ... - Nasdaq
www.nasdaq.com - September 14 at 12:57 AM |
| AmerisourceBergen's PharMEDium Slows Down, Competition Rife - Nasdaq
www.nasdaq.com - September 14 at 12:57 AM |
| Why the Earnings Streak Will Continue for Edwards Lifesciences (EW)
finance.yahoo.com - September 13 at 7:54 PM |
| Why the Earnings Streak Will Continue for Edwards Lifesciences (EW) - Nasdaq
www.nasdaq.com - September 13 at 12:22 AM |
| Top Medical Stock Trying To Pump Up New Breakout
finance.yahoo.com - September 12 at 7:18 PM |
| Insider Selling: Edwards Lifesciences Corporation (EW) CEO Sells 32,900 Shares of Stock
www.americanbankingnews.com - September 11 at 7:30 PM |
| Henry Schein MicroMD Software Gets ONC-Health IT Certificate ... - Nasdaq
www.nasdaq.com - September 11 at 7:02 PM |
| Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - September 8 at 6:54 PM |
| Abbott (ABT) Hits a 52-Week High: What's Driving the Stock? - Nasdaq
www.nasdaq.com - September 8 at 4:42 AM |
| Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite ... - Nasdaq
www.nasdaq.com - September 7 at 6:13 AM |
| Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN
finance.yahoo.com - September 6 at 6:25 PM |
| HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
finance.yahoo.com - September 6 at 6:24 PM |
| Edwards Lifesciences Near 52-Week High: Can It Sustain Momentum?
finance.yahoo.com - September 5 at 8:07 PM |
| FDA Approvals Could Drive Edwards Lifesciences’ Growth
finance.yahoo.com - September 5 at 8:07 PM |
| Edwards Lifesciences Corporation (EW) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 2 at 9:08 PM |
| BMO Capital Markets Reaffirms Buy Rating for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - September 2 at 10:38 AM |
| Edwards Lifesciences Corporation's (EW) "Buy" Rating Reaffirmed at Royal Bank Of Canada
www.americanbankingnews.com - September 2 at 6:56 AM |
| Haemonetics Grows on Strong Plasma, Blood Center Sluggish
finance.yahoo.com - September 1 at 6:49 PM |
 | Edwards Lifesciences To Present At The 12th Annual Wells Fargo Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - August 31 at 11:27 PM |
| VWR Awaits Merger Closure, Stock Upside Potential Limited
finance.yahoo.com - August 31 at 6:25 PM |
| Edwards Lifesciences To Present At The 12th Annual Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 6:25 PM |
| Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
finance.yahoo.com - August 31 at 6:25 PM |
| Intuitive Surgical (ISRG) Well Poised on Procedural Business
finance.yahoo.com - August 31 at 5:45 AM |
| Edwards Lifesciences (EW) Down 3.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - August 31 at 5:45 AM |
| NuVasive (NUVA) to Expand San Diego Global Headquarters
finance.yahoo.com - August 31 at 5:45 AM |
| Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now
finance.yahoo.com - August 30 at 7:42 PM |
| Thermo Fisher Acquires Patheon, Boosts Laboratory Products
finance.yahoo.com - August 30 at 7:42 PM |
| Donald E. Bobo, Jr. Sells 5,300 Shares of Edwards Lifesciences Corp (EW) Stock
www.americanbankingnews.com - August 30 at 7:34 PM |
| Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 18,960 Shares of Stock
www.americanbankingnews.com - August 30 at 7:16 PM |
Edwards Lifesciences Corporation (EW) Chart for Friday, September, 22, 2017
